AstraZeneca and Nomura Phase4 Ventures today announced the signing of a deal to form Albireo, a company focused on developing new treatments for gastrointestinal (GI) disorders.
Albireo, based in
read more » Discuss Add this link to...Bury Add to:
| Bookmarks